TY - JOUR
AU - Robb, Calum
AU - Goepp, Marie
AU - Rossi, Adriano G.
AU - Yao, Chengcan
PY - 2020
DA - July
TI - Non-steroidal anti-inflammatory drugs, prostaglandins and COVID-19
JO - British Journal of Pharmacology
EP - 4920
VL - 177
IS - 21
DO - https://doi.org/10.1111/bph.15206
AB - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of the novel coronavirus disease 2019 (COVID-19), a highly pathogenic and sometimes fatal respiratory disease responsible for the current 2020 global pandemic. Presently, there remains no effective vaccine nor efficient treatment strategies against COVID-19. Non-steroidal anti-inflammatory drugs (NSAIDs) are medicines very widely used to alleviate fever, pain and inflammation (common symptoms of COVID-19 patients) through effectively blocking production of prostaglandins (PGs) via inhibition of cyclooxygenase enzymes. PGs can exert either pro- or anti-inflammatory effects depending on the inflammatory scenario. In this review, we implicate the potential roles that NSAIDs and PGs may play during SARS-CoV-2 infection and the development and progression of COVID-19.
PB - Wiley
UR - https://www.research.ed.ac.uk/portal/en/publications/nonsteroidal-antiinflammatory-drugs-prostaglandins-and-covid19(c4384ead-b311-4575-80cb-5bb93b75d261).html
KW - Coronavirus (COVID-19)
ER